1/6
07:00 am
mcrb
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
Low
Report
Seres Therapeutics Announces Publications in Nature Medicine and Journal of Infectious Diseases Highlighting Vowst™ Mechanism of Action and Supporting Broader Live Biotherapeutic Strategy
11/24
07:00 am
mcrb
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
Medium
Report
Seres Therapeutics to Participate in Piper Sandler Healthcare Conference
11/18
01:20 pm
mcrb
Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
High
Report
Seres Therapeutics (NASDAQ:MCRB) had its "sell (d)" rating reaffirmed by analysts at
Weiss Ratings.
11/5
07:00 am
mcrb
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
Medium
Report
Seres Therapeutics Reports Third Quarter 2025 Financial Results and Provides Business Updates
10/30
07:00 am
mcrb
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
Medium
Report
Seres Therapeutics to Announce Third Quarter 2025 Financial Results and Business Updates on November 5, 2025
10/29
07:00 am
mcrb
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155
Low
Report
Seres Therapeutics Receives Award of Up to $3.6 Million from CARB-X to Develop Liquid Formulation of SER-155